Abstract Number: 1448 • ACR Convergence 2022
Utility of Digital Signals and Patient Reported Data Gathered in a Decentralized Study to Predict SLE Patient-Reported Flares
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease characterized by varied immune dysregulation. SLE patients often experience episodic flares, leading to organ damage…Abstract Number: 1954 • ACR Convergence 2022
Development of the Patient-Important Outcomes Data Repository (PIONEER) for Rheumatic Diseases; An Enhanced Database Combining Electronic Medical Data with Insight from Chart Reviews
Background/Purpose: Clinical and non-clinical forces contribute to real-world treatment effectiveness, yet most studies focus on efficacy in an idealized setting. To identify factors impacting clinical…Abstract Number: 2243 • ACR Convergence 2022
Patient Reported Outcomes from a Randomized Phase 3 Trial of Sarilumab in Polymyalgia Rheumatica
Background/Purpose: Polymyalgia rheumatica (PMR) is a common inflammatory rheumatic disease in the elderly. The phase 3 SAPHYR trial (NCT03600818) assessed the efficacy and safety of…Abstract Number: 0187 • ACR Convergence 2022
Patient-reported Outcomes and Quality of Life in Patients with Rheumatoid Arthritis Treated with GP2015: Final Results from a Real-world Study
Background/Purpose: COMPACT is a non-interventional study evaluating the persistence, effectiveness, safety and patient-reported outcomes (PROs) in patients with rheumatoid arthritis (RA), axial-spondyloarthritis or psoriatic arthritis…Abstract Number: 0313 • ACR Convergence 2022
Olokizumab Improves Patient Reported Outcomes in Moderate to Severely Active Rheumatoid Arthritis Patients Inadequately Controlled by Methotrexate (MTX-IR): Results from the Phase III Randomized Controlled Trial
Background/Purpose: Olokizumab (OKZ) is an interleukin-6-inhibitor for treatment of Rheumatoid Arthritis (RA). In these analyses, we present patient reported outcomes (PROs) reported by MTX-IR patients…Abstract Number: 0444 • ACR Convergence 2022
Prevalence of Frailty and Associated Factors in Patients with Vasculitis
Background/Purpose: Frailty is a syndrome characterized by an increased vulnerability to stressors and is associated with disability and early mortality. Frailty may be accelerated in…Abstract Number: 0855 • ACR Convergence 2022
Change in Short Term Outcomes Following Tolerated Disease Activity Level for Individuals with Juvenile Idiopathic Arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry
Background/Purpose: Current recommendations suggest treatment escalation for juvenile idiopathic arthritis (JIA) until the disease activity target is reached, ideally inactive or low disease activity. Our…Abstract Number: 1336 • ACR Convergence 2022
Productivity Analysis in Patients with Idiopathic Inflammatory Myopathies and Relationship with Quality of Life and Emotional Domain: Preliminary Data from a Monocentric Cohort
Background/Purpose: Idiopathic Inflammatory Myopathies (IIM) are chronic diseases often causing disability in patients, associated with both disease activity and damage accrual. These conditions might reduce…Abstract Number: 1451 • ACR Convergence 2022
Delayed Sleep Phase Syndrome Characterizes Circadian Disorder in Patients with Active SLE
Background/Purpose: Poor sleep quality is a common complaint of patients with SLE. Although chronic sleep disruption is known to drive circadian rhythm disorders, the effects…Abstract Number: 1973 • ACR Convergence 2022
Association Between Activity Limitations, Sleep Disturbance, Pain Sensitivity, Pain Intensity, and Widespread Pain in Adults with Rheumatoid Arthritis
Background/Purpose: Despite treatment with strong immunosuppressive medications, more than half of patients with rheumatoid arthritis (RA) still report pain. Pain can spread from joint sites…Abstract Number: 2246 • ACR Convergence 2022
Rheumatoid Arthritis Patient Discordance with Provider Treatment Goals Is Associated with Poorer RA Outcomes
Background/Purpose: We previously reported on themes in rheumatoid arthritis (RA) patients' treatment goals which associated with aspects of rheumatology care such as presence of a…Abstract Number: 0191 • ACR Convergence 2022
Patient-reported Outcomes to Assess Dyspnea in Connective Tissue Diseases, Interstitial Lung Disease and Pulmonary Hypertension, a Systematic Literature Review of Measurement Properties
Background/Purpose: This COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN)-based systematic review aims to identify and summarize the quality of measurement properties of…Abstract Number: 0314 • ACR Convergence 2022
Olokizumab Improved Patient Reported Outcomes in TNF Incomplete Responder (TNF-IR) Rheumatoid Arthritis Patients: Results from the Phase III Randomized Controlled Trial
Background/Purpose: Olokizumab (OKZ) is an interleukin-6-inhibitor for treatment of rheumatoid arthritis (RA). In these analyses we present patient reported outcomes (PROs) reported by TNF-IR patients…Abstract Number: 0503 • ACR Convergence 2022
The Effect of Social Isolation on 1-Year Outcomes After Surgical Repair of Low Trauma Hip Fracture
Background/Purpose: Hip fractures are a serious public health issue with a significant population burden, especially among those over 65 years old. Social isolation—how integrated a…Abstract Number: 0863 • ACR Convergence 2022
Effect of Glucocorticoids on Patient Reported Outcomes in Patients Started on a Biologic Consensus Treatment Plan for the ‘First Line Options for Systemic JIA Treatment’ (FROST) Study
Background/Purpose: Systemic Juvenile Idiopathic Arthritis (sJIA) is a systemic autoinflammatory disease characterized by high fevers, rash and arthritis. Current treatment regimens often involve biologic (anti-IL-1…
- « Previous Page
- 1
- …
- 25
- 26
- 27
- 28
- 29
- …
- 50
- Next Page »